South Korean biopharmaceutical startup using AI-driven chemical proteomics and precision covalent drug design to discover novel therapeutic targets and develop small-molecule medicines, including oncology and hematology candidates
South Korean biopharmaceutical startup using AI-driven chemical proteomics and precision covalent drug design to discover novel therapeutic targets and develop small-molecule medicines, including oncology and hematology candidates.